▎Edited by the WuXi AppTec content team
As Moderna and Merck & Co., Inc. announced the pivotal clinical trial results of their jointly developed cancer vaccine mRNA-4157, cancer vaccines have gained widespread attention as an emerging approach to cancer treatment. At the recent 2024 World Vaccine Congress (WVC), Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) under the U.S. FDA, stated in regard to cancer vaccines,FDA Is Ready to Review These Disruptive New Cancer Vaccines, Signaling a New Chapter in Cancer ImmunotherapyWhat is a cancer vaccine?
Cancer Vaccines: An Emerging Immunotherapy StrategyCancer vaccines represent an emerging immunotherapy strategy designed to train the immune system to recognize and eliminate cancer cells. These vaccines are broadly categorized into two types: prophylactic (preventive) vaccines and therapeutic vaccines.Preventive vaccines reduce the risk of certain cancers by preventing specific viral infections, while therapeutic cancer vaccines aim to treat existing cancers.Therapeutic cancer vaccines stimulate an immune response by exposing the immune system to molecules associated with specific types of cancer, enabling the immune system to recognize and eliminate cancer cells.Therapeutic vaccines are typically composed of specific cancer antigens and adjuvants, which act on the immune system to enhance the vaccine's efficacy.
With the development of sequencing technology, the field of cancer vaccine research and development is advancing rapidly.Scientists have identified new abnormal proteins (i.e., neoantigens) produced by DNA mutations in cancer cells, providing new targets for vaccine design.The discovery of these new antigens provides a new direction for the development of therapeutic cancer vaccines and also promotes the evolution of cancer treatment towards personalized medicine.Cancer Vaccine Co-developed by Moderna and MSDmRNA-4157 contains a single synthetic mRNA molecule encoding up to 34 neoantigens, which are algorithmically designed based on the unique DNA mutation profile of each patient's tumor.When this cancer vaccine is injected into the body, the neoantigen sequences carried by these RNAs are translated into proteins and, through antigen presentation in the body, stimulate T-cell anti-tumor responses.Artificial Intelligence (AI) Plays a Key Role in the Development of mRNA-4157，IncludingRapidly Obtain Next-Generation Sequencing Data from Tumor and Blood Samples, Analyze Their Gene Mutations, and Predict Neoantigens Most Likely to Trigger Immune ResponsesOver time, this algorithm can learn by pairing clinical and immunogenicity data, and is expected to better screen out the most clinically active neoantigens.
Despite the tremendous potential of artificial intelligence in the development of cancer vaccines like mRNA-4157, its use has also introduced new variables, particularly in terms of regulation. While the goal of developing therapeutic cancer vaccines is to demonstrate their efficacy through conventional clinical endpoints such as tumor progression and overall survival, the innovative nature of AI technology presents novel regulatory challenges. To address this issue, the U.S. FDA and the biopharmaceutical industry are seeking new review approaches to tackle these challenges.Regulatory Challenges Facing AI-Developed Cancer Vaccines
In the development of the mRNA-4157 vaccine, AI played a crucial role by guiding how to customize personalized vaccines to combat cancer. Based on neoantigen sequences identified by AI algorithms, the proteins produced may vary from person to person.Given that AI algorithms evolve with the input of new information, to ensure the integrity and reliability of AI-based vaccine clinical trials, vaccine development companies must "lock" the algorithm before the study begins, preventing any potential changes from affecting the study results.。Dr. Kyle Holen, Head of Therapeutics Development and Oncology at Moderna, noted that given the central role of artificial intelligence in this program, Moderna anticipates that the FDA will require a thorough review of the algorithms when evaluating vaccines like mRNA-4157.This raises a new regulatory issue:To what extent can AI algorithms be modified before considering vaccines as entirely new products?Although Moderna has begun internal discussions on this issue, no clear conclusion has been reached so far. This challenge highlights the importance of regulatory frameworks continuously adapting to technological advancements in the highly innovative medical field.Facing Challenges, What Does the FDA Plan to Do?
Moderna has communicated with the U.S. FDA regarding its mRNA-4157 vaccine program to discuss the impact of changing sequencing suppliers and adjusting the range of antigen quantities. These changes will be considered significant modifications to the program. However,It is not yet clear whether these adjustments will require the submission of a new supplemental application, or if a completely new drug application must be submitted for any significant changes after the initial approval.According to the industry media Fierce Biotech,Dr. Peter Marks of the FDA seems to lean towards stricter review standards for updates to cancer vaccines, treating the modified products as new ones.
Considering that cancer vaccines may need to be updated frequently, it seems impractical to require a full review or large randomized clinical trials for each update. Therefore, Dr. Marks proposed,The platform technology designation under consideration by the U.S. FDA may provide a solution to this issue.。FDA Recently Released a Draft Guidance on the "Advanced Manufacturing Technology" Designation ProgramThis move aims to promote product development and improvements in the pharmaceutical production process through new technologies. The FDA is still separately formulating specific guidelines for the designation of "platform technology," with the goal of allowing products developed using the same platform technology to benefit from a more streamlined review process.Although the FDA proposed the concept of "platform technology designation" some time ago, Dr. Marks pointed out that the concept has not been fully applied. He emphasized,The application of mRNA technology will force the FDA to actively explore and expand the application scope of this concept to adapt to the development of emerging technologies.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
[1] 'We're open for business': FDA's Peter Marks says agency ready to review novel cancer vaccines despite unknowns，Retrieved April 8, 2024 from https://www.fiercebiotech.com/biotech/were-open-business-fdas-peter-marks-says-agency-ready-review-novel-cancer-vaccines-despite[2] Advancing the Fight Against Cancer through mRNA & AI，Retrieved April 8, 2024 from https://www.modernatx.com/en-US/media-center/all-media/blogs/advancing-fight-against-cancerDisclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.
Share，PointLike，In View, Focus on Global Biomedical Health Innovation
